// STARTUP COMPARISON
Nexura vs Limeade Israel
Nexura failed in 2020 due to Bad Timing. Limeade Israel failed in 2021 due to Acquisition Gone Wrong. Different causes, different sectors, different eras — but the same simulation outcome.
| METRIC | 🔥 Nexura | 🔥 Limeade Israel |
|---|---|---|
| Sector | Healthtech | Healthtech |
| Country | Colombia | Israel |
| Founded | 2017 | 2014 |
| Died | 2020 | 2021 |
| Raised | $2M | $30M |
| Peak | 50 clinic partners | $30M raised |
| Primary Cause | Bad Timing | Acquisition Gone Wrong |
// WHY EACH FAILED
🔥 Nexura
Bad Timing
Nexura built a telemedicine platform connecting Colombian patients with specialist doctors. It had 50 clinic partnerships when COVID-19 hit in March 2020. The pandemic initially seemed like a tailwind — telemedicine demand exploded. But well-funded competitors including Doctoralia, Doctoranytime, and hospital-backed platforms entered the market simultaneously with COVID-era capital. Nexura could not compete for physician supply or patient acquisition against better-capitalized entrants.
// LESSON
A pandemic tailwind attracts well-funded competition as fast as it creates demand. If you're the underfunded incumbent when the tailwind hits, you get flooded, not lifted. Raise ahead of the macro event, not during it.
A pandemic tailwind attracts well-funded competition as fast as it creates demand. If you're the underfunded incumbent when the tailwind hits, you get flooded, not lifted. Raise ahead of the macro event, not during it.
🔥 Limeade Israel
Acquisition Gone Wrong
Limeade built an employee wellbeing and engagement platform with significant Israeli R&D operations. After raising $30M, Roper Technologies acquired the company in 2021. Post-acquisition the Israeli engineering center was deprioritized as Roper focused on integrating Limeade's US commercial operations. Key Israeli engineers departed and the product development velocity declined significantly.
// LESSON
Israeli R&D centers acquired by US companies need explicit contractual protection of headcount and roadmap independence. Without it, the US commercial integration absorbs all management attention and the R&D center becomes a cost center that gets rationalized.
Israeli R&D centers acquired by US companies need explicit contractual protection of headcount and roadmap independence. Without it, the US commercial integration absorbs all management attention and the R&D center becomes a cost center that gets rationalized.
// EXPLORE FURTHER